Hepatitis B Immunoglobulin
Hepatitis B Immunoglobulin - Related Videos
04:48
A Paper-Based Immunoassay for the Detection of Immunoglobulin G
0 Views •
2025
The video demonstrates a paper-based immunoassay, involving amine-functionalized cellulose discs cross-linked with glutaraldehyde. Covalent immobilization of IgG-Fc-specific capture antibodies, followed by the introduction of immunoglobulin G and horseradish peroxidase-conjugated detection antibodies, results in a color change confirming the presence of immunoglobulin G.
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
0 Views •
Cited by 2 •
2017
Here we describe a newly developed hepatitis B virus (HBV) reporter system to monitor the early stages of the HBV life cycle. This simplified in vitro system will aid in the screening of anti-HBV agents using a high-throughput strategy.
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
0 Views •
Cited by 2 •
2014
Hepatitis C Virus (HCV) is a major human pathogen that causes liver disorders, including cirrhosis and cancer. An HCV infectious cell culture system is essential for understanding the molecular mechanism of HCV replication and developing new therapeutic approaches. Here we describe a protocol to investigate various stages of the HCV replication cycle.
03:31
A Microfluidic Cartridge-Based Detection System for Allergen-Specific Immunoglobulin E
0 Views •
2025
This video demonstrates a protocol for detecting serum-specific immunoglobulin E using a microfluidic cartridge-based chemiluminescence system. Serum IgEs interact with distinct allergens immobilized in the reaction zone of the cartridge, which are subsequently detected with peroxidase-conjugated anti-IgE antibodies and a chemiluminescent substrate, allowing simultaneous detection of multiple allergen-specific IgEs.
04:51
Measuring Immunoglobulin G Levels Against a Test Vaccine in a Mouse Serum
0 Views •
2025
This video demonstrates a method for assessing the antibody immune response to a novel nanoemulsion adjuvant vaccine in pre-immunized mice. Immunization enhances antibody response as confirmed by determining the IgG antibody titers.
FAQs
The preparation supplies anti-HBs antibodies that recognize hepatitis B surface antigen on circulating virus and viral particles. By binding these targets, the antibodies can limit the virus’s ability to enter susceptible cells and establish infection. This immediate antibody-mediated barrier is especially important during the interval before the exposed person develops an effective adaptive immune response.
HBIG provides passive protection because it supplies ready-made antibodies rather than stimulating the recipient to generate durable immunity. Its main value is immediate coverage when exposure has already occurred or when early protection is needed. Hepatitis B vaccination addresses the longer-term immunologic need by promoting active immunity, so the two approaches serve different purposes.
The combination pairs immediate passive antibody protection with the longer-term response generated by vaccination. HBIG can act before an adaptive response develops, while vaccination promotes durable active immunity. Using both approaches therefore addresses different stages of prevention and improves protection against infection and chronic infection compared with relying on the immediate antibody preparation alone.
HBIG is used after exposure to blood or body fluids from a source associated with hepatitis B infection. In this setting, its immediate antibody activity helps address the risk before the exposed person’s adaptive immune response develops. Hepatitis B vaccination is often administered as part of prevention, adding a pathway toward durable active immunity after the exposure.
Newborns of mothers with hepatitis B represent a specific clinical setting in which HBIG is used to provide early protection against infection. The preparation supplies anti-HBs antibodies during a period when an infant may not yet have developed an effective adaptive response. Hepatitis B vaccination is also used, combining immediate passive protection with development of longer-term active immunity.
HBIG has a role in selected liver-transplant settings, where clinicians may use antibody-based protection as part of hepatitis B management. Its relevance comes from the ability of anti-HBs antibodies to bind circulating virus and surface antigens, helping prevent viral entry and establishment while broader preventive or immune strategies are considered in the transplant context.